BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16583487)

  • 1. Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-alpha.
    Fitch PG; Cron RQ
    J Rheumatol; 2006 Apr; 33(4):825; author reply 826-7. PubMed ID: 16583487
    [No Abstract]   [Full Text] [Related]  

  • 2. Septic arthritis caused by Actinobacillus ureae in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha therapy.
    Kaur PP; Derk CT; Chatterji M; Dehoratius RJ
    J Rheumatol; 2004 Aug; 31(8):1663-5. PubMed ID: 15290751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept.
    Elwood RL; Pelszynski MM; Corman LI
    Pediatr Infect Dis J; 2003 Mar; 22(3):286-8. PubMed ID: 12664882
    [No Abstract]   [Full Text] [Related]  

  • 4. Borreliosis in a patient treated with anti-TNFα therapy: first case.
    Bonnet N; Guis S; Drancourt M; Brouqui P; Berbis P
    J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):367-8. PubMed ID: 20524947
    [No Abstract]   [Full Text] [Related]  

  • 5. Parapharyngeal abscess in a patient receiving etanercept.
    Borrás-Blasco J; Nuñez-Cornejo C; Gracia-Perez A; Rosique-Robles JD; Casterá MD; Viosca E; Abad FJ
    Ann Pharmacother; 2007 Feb; 41(2):341-4. PubMed ID: 17227824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis.
    Spadaro A; Ceccarelli F; Scrivo R; Valesini G
    Ann Rheum Dis; 2008 Nov; 67(11):1650-1. PubMed ID: 18854519
    [No Abstract]   [Full Text] [Related]  

  • 7. Relapsing oligoarticular septic arthritis during etanercept treatment of rheumatoid arthritis.
    Mor A; Mitnick HJ; Greene JB; Azar N; Budnah R; Fetto J
    J Clin Rheumatol; 2006 Apr; 12(2):87-9. PubMed ID: 16601543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?
    Khanna D; McMahon M; Furst DE
    Arthritis Rheum; 2004 Apr; 50(4):1040-50. PubMed ID: 15077286
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
    Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy.
    Mangge H; Gindl S; Kenzian H; Schauenstein K
    J Rheumatol; 2003 Nov; 30(11):2506-7. PubMed ID: 14677200
    [No Abstract]   [Full Text] [Related]  

  • 12. Taiwan experience with etanercept in juvenile rheumatoid arthritis.
    Lai JH
    J Microbiol Immunol Infect; 2005 Dec; 38(6):451-4. PubMed ID: 16341348
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis.
    Giannini EH; Ilowite NT; Lovell DJ; Wallace CA; Rabinovich CE; Reiff A; Higgins G; Gottlieb B; Chon Y; Zhang N; Baumgartner SW
    Arthritis Rheum; 2010 Nov; 62(11):3259-64. PubMed ID: 20669280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purulent pericarditis in a patient with rheumatoid arthritis treated with etanercept and methotrexate.
    Sweet DD; Isac G; Morrison B; Fenwick J; Dhingra V
    CJEM; 2007 Jan; 9(1):40-2. PubMed ID: 17391602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory idiopathic thrombocytopenic purpura treated with the soluble tumor necrosis factor receptor etanercept.
    Litton G
    Am J Hematol; 2008 Apr; 83(4):344. PubMed ID: 18186526
    [No Abstract]   [Full Text] [Related]  

  • 17. Etanercept in psoriasis treatment.
    Pietrzak A; Chodorowska G; Urban J; Roliński J; Pietrzak B
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):222-6. PubMed ID: 15314989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are glucocorticoids a consistent risk factor for infections in rheumatoid arthritis patients under treatment with methotrexate and etanercept?
    Luzi G; Laganà B; Salemi S; Di Rosa R
    Clin Ter; 2009; 160(2):121-3. PubMed ID: 19452100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis].
    Pontikaki I; Gerloni V; Gattinara M; Luriati A; Salmaso A; De Marco G; Teruzzi B; Valcamonica E; Fantini F
    Reumatismo; 2006; 58(1):31-8. PubMed ID: 16639486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.